Kodak Adds Normal Saline to Pharmaceutical Portfolio

Kodak has added Normal Saline to its pharmaceutical portfolio and debuted a U.S. online store, according to Chaindrugreview. The publication reported that the Normal Saline addition builds on Kodak’s portfolio of sterile, ready-to-use buffers and reagents.

Chaindrugreview said these buffers and reagents are manufactured in Kodak’s U.S.-based, FDA-registered cGMP facility. The reported launch places Normal Saline within the company’s stated pharmaceutical portfolio activity.

Normal Saline joins the portfolio

The product announcement centers on Normal Saline as a new addition to Kodak’s pharmaceutical portfolio. Chaindrugreview characterized the broader portfolio as including sterile, ready-to-use buffers and reagents.

For medical and pharmaceutical sales professionals tracking portfolio changes, the update identifies Normal Saline as the newly launched product and connects it with Kodak’s existing sterile, ready-to-use materials. Chaindrugreview did not provide further product specifications in the supplied report.

Manufacturing context

Chaindrugreview reported that Kodak’s sterile, ready-to-use buffers and reagents are manufactured at a U.S.-based, FDA-registered cGMP facility. That manufacturing detail accompanies the publication’s coverage of the Normal Saline launch.

The report describes the facility in connection with Kodak’s growing portfolio of buffers and reagents. The Normal Saline announcement extends that portfolio, according to Chaindrugreview.

U.S. online store debut

Alongside the portfolio addition, Kodak debuted a U.S. online store, Chaindrugreview reported. The store debut was announced with the Normal Saline launch rather than as a separate event in the supplied evidence.

Chaindrugreview’s report therefore combines two developments: the addition of Normal Saline to Kodak’s pharmaceutical portfolio and the debut of a U.S. online store. The evidence identifies sterile, ready-to-use buffers and reagents, along with the U.S.-based, FDA-registered cGMP facility, as context for the announcement.